Personalized Treatment in Cancer Research, Second Edition
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 December 2025
Special Issue Editors
Interests: pharmacology; sex and gender medicine; pharmacokinetics; pharmacodynamics; pharmacogenomics; personalized therapy
Special Issues, Collections and Topics in MDPI journals
Interests: gender pharmacology; gender medicine; pharmacokinetics; pharmacogenomics; personalized therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
In oncology, personalized medicine is an emerging approach for tumour therapy that takes into consideration the interindividual variability in treatment outcome and toxicity of each cancer patient. Personalization has the potential to tailor therapy towards the pharmacogenetic and pharmacokinetic drivers of treatment outcome and thus on patient quality of life. Furthermore, this could be the key to avoiding suboptimal drug dosing or adverse events, taking into account the genetic variability of each person, their sex and their age.
The Special Issue, “Personalized Treatment in Cancer Research, Second Edition”, will focus on tailored treatment in cancer research, including clinical, pharmacological and translational studies.
Dr. Silvia De Francia
Dr. Sarah Allegra
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Cancer
- personalized medicine
- personalized treatment
- pharmacogenetics
- pharmacokinetics
- chemotherapy
- adjuvant treatment
- therapeutic drug monitoring
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issue
- Personalized Treatment in Cancer Research in Biomedicines (5 articles)
